Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen to swallow $1.16B Micromet in one BiTE, like a cytotoxic T cell on a tumour

This article was originally published in Scrip

Executive Summary

Amgen has collaborated with Micromet on its BiTE novel oncology platform since last July and it obviously has liked what it has seen, and then in December it heard news of promising Phase II data with a Micromet molecule for acute lymphocytic leukaemia (ALL), a difficult to treat blood cancer. This has now culminated in Amgen’s announcement that it will acquire Micromet for $11 per share in cash, for a total of around $1.16 billion, a 33% premium over the company’s closing price of $8.28 just before the deal was announced.

Advertisement

Related Content

Amgen's Oncology Strategy: Building A Pipeline Of Novel Paradigm-Changing Drugs
TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients
Interview: Amgen's BiTE Platform Becomes A Feast As More Molecules Enter The Clinic
R&D Head Sean Harper On Amgen's Long-Term Investment View
Finance Watch: Bicycle Spins Toward Clinic With $52m Round; Stock Spikes Spur Offerings
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016074

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel